Shilpa Medicare Incorporated in 1987 manufactures niche APIs, intermediates, and formulations and also undertakes contract research and manufacturing service for some of its customers. The company’s formulation products consist of 16 injectable dosage forms, 19 oral solid dosage forms under SML and 13 formulations under SML’s wholly owned subsidiary Shilpa Therapeutics.
Financial Results:
Shilpa Medicare Ltd reported Revenues for Q1FY24 of ₹260.00 Crores down from ₹261.00 Crore year on year, a fall of 0.38%.
Total Expenses for Q1FY24 of ₹259.00 Crores down from ₹273.00 Crores year on year, a fall of 5.13%.
Consolidated Net Profit of ₹1.00 Crores down 50.0% from ₹2.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹0.14, up 40.00% from ₹0.10 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.